Stockscreener 앱 받기
3.6008
4.32%
-0.1592
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Wolfe Research Initiates Coverage of CytomX Therapeutics (CTMX) with Outperform - Insider Monkey
CytomX Therapeutics to Present at Upcoming June Investor Conferences - The Manila Times
CytomX Therapeutics in June investor events at Jefferies, Goldman Sachs - Stock Titan
CTMX Stock Price, Quote & Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Wolfe Research initiates CytomX stock with outperform rating By Investing.com - Investing.com Australia
Wolfe Research Initiates CytomX Therapeutics With Outperform Rating - Moomoo
Wolfe Research initiates CytomX stock with outperform rating - Investing.com
CytomX appoints Mamata Gokhale as regulatory affairs head By Investing.com - Investing.com Australia
CytomX appoints Mamata Gokhale as regulatory affairs head - Investing.com
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory ... - Caledonian Record
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs - Yahoo Finance
Cantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight Recommendation - MSN
Seven Fleet group beneficially owns 1,085,398 CTMX shares (NASDAQ: CTMX) - Stock Titan
Longitude funds, managers report sizable CTMX stakes (CTMX) — 7.0% by principals - Stock Titan
Venrock group files Amendment reporting 9.98M CTMX shares (NASDAQ: CTMX) - Stock Titan
Kynam Capital (CTMX) discloses 15.0M-share, 6.90% stake in CytomX (Schedule 13G/A) - Stock Titan
Perceptive (CTMX) reports 10,098,824 shares, a 4.6% stake - Stock Titan
CytomX’s CX-801 Enters Key Early Cancer Trial Phase, Putting CTMX Back on Investor Radar - TipRanks
CytomX Therapeutics stock (US23284F1057): Recent price volatility draws attention - AD HOC NEWS
Brokers Are Upgrading Their Views On CytomX Therapeutics, Inc. (NASDAQ:CTMX) With These New Forecasts - 富途牛牛
HC Wainwright Analysts Increase Earnings Estimates for CTMX - MarketBeat
Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher - simplywall.st
New Forecasts: Here's What Analysts Think The Future Holds For CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Yahoo Finance
Earnings call transcript: CytomX Therapeutics Q1 2026 beats EPS forecast - Investing.com UK
Earnings call transcript: CytomX Therapeutics Q1 2026 beats EPS forecast By Investing.com - Investing.com Nigeria
CTMX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts CytomX stock price target on trial data By Investing.com - Investing.com South Africa
Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates - 富途牛牛
Earnings Beat: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
H.C. Wainwright cuts CytomX stock price target on trial data - Investing.com
CytomX Therapeutics: Early-Stage Pipeline, Trial Setbacks and High Risks on the Road to Profitability - TipRanks
CytomX Earnings Call Highlights Varseta-M Momentum - TipRanks
CytomX (CTMX) Q1 2026 Earnings Transcript - AOL.com
CytomX Q1 2026 slides: Varseta-M shows 32% response in CRC trial - Investing.com Canada
Earnings call transcript: CytomX Therapeutics beats Q1 2026 forecasts - Investing.com UK
CytomX Therapeutics (CTMX) Prepares for Transformational Year in 2026 - GuruFocus
Earnings call transcript: CytomX Therapeutics beats Q1 2026 forecasts By Investing.com - Investing.com India
CytomX Therapeutics (CTMX) reports Q1 loss, beats revenue estimates - MSN
CytomX Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CytomX Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) Q1 2026 Revenue Beat Sparks Cautious Market Rally - ChartMill
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
CytomX Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (CTMX) CytomX Therapeutics, Inc. Reports Q1 Revenue $10.3M, vs. FactSet Est of $4.7M - marketscreener.com
Q1 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
2.25%
0.46%
자본화:
|
볼륨(24시간):